CD BioGlyco's glycan biomarker discovery platforms can process various biological samples, and the optimized technology platforms can achieve ultra-high precision to help customers advance projects more accurately and quickly. We have confidence to be your essential research assistant in the field of glycobiology.
Protein glycosylation is a common post-translational modification sensitive to changes in the cellular environment. Glycosylation plays an important role in most life processes, such as protein folding, cell-to-cell interactions, receptor binding, etc. Abnormal glycosylation is associated with many diseases, including cancer, Parkinson's disease and cardiovascular disease. Glycans are different from nucleic acids and proteins as genetic templates do not directly encode them. Instead, they are dynamically assembled in hundreds of enzymes through more than a dozen complex biosynthetic pathways. Any influence on enzyme activity or any environmental changes will interfere with the final structure of glycans. Ample evidence has demonstrated the presence of abnormal N-glycosylation patterns on tumor cells, and these findings have inspired the search for glycan-based biomarkers in biological samples such as serum and plasma.
Glycans can represent biomarkers, indicating diseases with high sensitivity and specificity, and show great promise in distinguishing between healthy and diseased individuals. However, due to the need for complex sample preparation, the current methods for analyzing glycans are not suitable for clinical laboratories. Levels of complexity associated with protein glycosylation are hindering its development. Advanced strategies are needed to cope with challenges such as sample preparation, sample throughput, expensive instrumentation, and difficult data analysis in order to transfer the valuable knowledge provided by protein glycosylation to the clinical application.
Fig 1. Glycan biomarkers discovery unmet clinical needs (Shipman, J.T. et al. 2020)
CD BioGlyco's team of analysts is experienced in the discovery, validation, and verification of glycan biomarkers. Our technology platforms combine traditional and new technologies, including MALDI-TOF MS, nano-LC MS/MS, and microarrays, to achieve ultra-sensitive detection capabilities, which can be used for single-factor and multi-factor detection of a variety of biological substrates. For exploratory research and pre-clinical research, our technology platforms can be used to discover and verify the effectiveness of new biomarkers. In clinical studies, we can monitor the activity of biological drugs by detecting therapeutic targets. We use professional knowledge and the most advanced technology to promote and monitor drug development and bring convenience to customers.
CD BioGlyco provides first-class glycan biomarker discovery platforms that can process various types of biological samples. We do our best to help customers with biomedical transformation and our broad vision can provide customers with high-quality technical support.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.